Friday, June 26, 2020


AGTC Applied Genetic Technologies Corp. gains 20% Jun 26, 2020

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited. The company was founded in 1999 and is headquartered in Alachua, Florida.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive